Thrombocytopenia Clinical Trial
Official title:
Effect of Hemodialysis Membranes on Platelet Count
Verified date | February 2014 |
Source | Northwell Health |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Observational |
The purpose of this study is to determine if there is a drop in platelet count after hemodialysis. Hemodialysis membranes are known to activate complement and cause a drop in platelets and sometimes in white blood cells. The investigators are going to study one of the membranes which is the Fresenius Optiflux® to check if it causes a drop in platelets.
Status | Completed |
Enrollment | 99 |
Est. completion date | September 2011 |
Est. primary completion date | September 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 90 Years |
Eligibility |
Inclusion Criteria: - Patients on Hemodialysis for >=6 months Exclusion Criteria: - Hematological Cancers - Myelodysplastic syndromes - Baseline thrombocytopenia - Acute infections (patients on antibiotics) - Patients with Immune thrombocytopenic purpura (ITP)/Thrombotic thrombocytopenic purpura (TTP) - HIV - Liver disease |
Observational Model: Case Control, Time Perspective: Cross-Sectional
Country | Name | City | State |
---|---|---|---|
United States | Island Rehabilitative Service | Staten Island | New York |
Lead Sponsor | Collaborator |
---|---|
Northwell Health | Staten Island University Hospital |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Drop in platelet counts | 90 minutes through hemodialysis and immediately after finishing hemodialysis | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04003220 -
Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
|
||
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT03633019 -
High-dose Use of rhTPO in CIT Patients
|
Phase 4 | |
Recruiting |
NCT06087198 -
Clinical Performance Evaluation of T-TAS®01 HD Chip
|
||
Recruiting |
NCT03605511 -
TTP and aHUS in Complicated Pregnancies
|
||
Active, not recruiting |
NCT03688191 -
Study of Sirolimus in CTD-TP in China
|
Phase 4 | |
Completed |
NCT02845609 -
Efficacy of Sialic Acid GNE Related Thrombocytopenia
|
Phase 2 | |
Recruiting |
NCT02241031 -
Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia
|
Phase 2/Phase 3 | |
Recruiting |
NCT02244658 -
Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia
|
Phase 3 | |
Terminated |
NCT01368211 -
Mirasol-Treated Platelets - (Pathogen Reduction Extended Storage Study)
|
Phase 2/Phase 3 | |
Unknown status |
NCT01196884 -
Immune Thrombocytopenia (ITP) Immune-Genetic Assessment
|
||
Completed |
NCT00039858 -
Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
|
Phase 4 | |
Completed |
NCT00787241 -
Platelet Count Trends in Pre-eclamptic Parturients
|
N/A | |
Completed |
NCT00001533 -
Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine
|
Phase 1 | |
Not yet recruiting |
NCT06036966 -
The Efficacy and Safety of Hetrombopag in Primary Prevention of Thrombocytopenia Induced by the Niraparib Maintenance in Advanced Ovarian Cancer Patients
|
Phase 2 | |
Completed |
NCT01791101 -
Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia.
|
Phase 2 | |
Recruiting |
NCT06053021 -
Antiplatelet Therapy for AIS Patients With Thrombocytopenia
|
N/A | |
Recruiting |
NCT03701217 -
Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05958511 -
Assessment of Risk Factors and Outcome of Thrombocytopenia in ICU Patients
|
||
Completed |
NCT04917679 -
Eltrombopag Plus Diacerein vs Eltrombopag in Adult ITP
|
Phase 2 |